(Total Views: 620)
Posted On: 12/08/2022 12:19:52 AM
Post# of 154119
Noureddin’ s presentation was basically his NASH conference poster prezie. Glück did the cancers and was over the moon at “never been seen” results albeit in small numbers. Sacha clearly described the HIV envelope, and total RO en vivo AAV assisted LL production even after a drop off after 8-9 days.
“ Great, so Glück needs to get on the phone and sell Regeneron or Celgene on Leronlimab. That's his job now. Pfizer is trying to take over NASH.”
Read More: https://investorshangout.com/post/newpost/605...z7mqwWQMhW
Flicks the cancer one. It was a great call. I stand by that.
“ Great, so Glück needs to get on the phone and sell Regeneron or Celgene on Leronlimab. That's his job now. Pfizer is trying to take over NASH.”
Read More: https://investorshangout.com/post/newpost/605...z7mqwWQMhW
Flicks the cancer one. It was a great call. I stand by that.
(0)
(0)
